Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00022412 · ClinicalTrials.gov registry record · Phase 2

Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
6
Study locations

NCT00022412: Completed Phase 2 study of Prostate Cancer, sponsored by University of Wisconsin, Madison.

NCT00022412 is a Phase 2 study of Prostate Cancer that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00022412, a Phase 2 study of Prostate Cancer, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
6
Study locations

Study Summary

RATIONALE: Doxercalciferol may be an effective way to treat localized prostate cancer before surgery. PURPOSE: Randomized phase II trial to study the effectiveness of giving doxercalciferol before surgery in treating patients who have localized prostate cancer.

Conditions Studied

Interventions

  • PROCEDURE conventional surgery
  • DIETARY_SUPPLEMENT doxercalciferol

Study Locations (6)

Wisconsin

  • Veterans Affairs Medical Center - Madison - Madison
  • Meriter Hospital - Madison
  • University of Wisconsin Comprehensive Cancer Center - Madison
  • Medical College of Wisconsin Cancer Center - Milwaukee

Iowa

  • Holden Comprehensive Cancer Center at University of Iowa - Iowa City

New York

  • James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2001-08
Est. Completion 2008-08
Phase Phase 2
University of Wisconsin, Madison

1,039 total trials

What the finished NCT00022412 record still lists

NCT00022412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which conventional surgery is the first listed.

NCT00022412 lists 6 locations in 3 states (Wisconsin, Iowa, New York).

Frequently Asked Questions

What is clinical trial NCT00022412 about?

NCT00022412 is a clinical study titled "Doxercalciferol Before Surgery in Treating Localized Prostate Cancer". RATIONALE: Doxercalciferol may be an effective way to treat localized prostate cancer before surgery. PURPOSE: Randomized phase II trial to study the effectiveness of giving doxercalciferol before surgery in treating patients who have localized prostate cancer.

What is the current status of trial NCT00022412?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-08. Estimated completion is 2008-08.

What conditions does trial NCT00022412 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00022412?

The interventions under investigation include: conventional surgery (PROCEDURE), doxercalciferol (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00022412?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00022412 being conducted?

This trial has 6 study locations across Iowa, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00022412's enrollment target sits among peer trials

60 421st of 735 higher than 293 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00022412, the US trial registry maintained by the National Library of Medicine. NCT00022412 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.